On the other hand, a study by Hanna GL et al. detected PD-L1 (clone 73–10) (a rabbit monoclonal recombinant antibody was used for the characterization) in about a quarter of MCC tumor cells, and PD-L1 in more than 90% of immune cells did not find a significant difference in overall survival and prognosis in patients who were not treated with ICI, including pembrolizumab, avelumab, and nivolumab [47]. This evidence concerns the gene CD274 and neoplasm.